Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
from what i have gathered from others this author was also short on DNDN.
Still Bullish on Chinese Microcap Stocks 3 comments
by: Bull in the China Market January 14, 2010 | about: TPI / NPD / CNAM.OB / CPHI / SIAF.PK Bull in the China Market 27
In April 2008, I recommended a portfolio of nine Chinese smallcap stocks (see “Bullish on Chinese Microcaps”). If you had invested an equal amount of money in each of these stocks, you would have realized a 39% gain during this period. In comparison, the S&P 500 declined 18% over the same time frame.
My biggest gain came Universal Travel (UTV), a web-based Chinese travel company, which I sold right before its move to the NYSE. I accumulated UTA at prices ranging from $1.41 to $9.75 and eventually sold at $14.90. I don’t hold any shares of it currently, but it looks increasingly attractive after its pullback to the $10 range. I continue to hold China Agritech, which actually fell below $1.00 per share before reaching the current price of $35. As these examples make clear, explosive gains were available in these little-known stocks.
And what about today? I remain bullish on Chinese microcaps, and anticipate that this may be one of the best performing sectors of the stock market over the next year. US investors are looking for more foreign exposure, and the valuations on these stocks remain very attractive.
Here are my five favorite picks for the year, each of which I hold in my personal portfolio:
SINO AGRO FOOD INC (SIAF.PK, current price =$1.37): Sino Agro is a diversified organic food company with a top notch CEO and strong ties to the Chinese government. This company is projecting $.32 EPS in 2010, but the share price is only $1.37. Can you really buy a growth stock in a hot economy at a PE level of under five? Yes, you can, and this is exactly why these microcaps are the place to be in 2010.
CHINA PHARMA HLDGS (CPHI, current price = $4.05): I like Chinese healthcare stocks, because they are not dependent on exports to the US and Europe—dicey in the current environment—but rather serve home-grown consumers, with their rising standards of living. China Pharma sells pharmaceutical and nutritional supplements, and recently reported 23% growth in sales year-on-year, and a 70% growth in EPS. Yet the PE ratio is under ten.
CHINA ARMCO METALS (CNAM.OB, current price = $4.00): This company is expanding from its metal distribution business into metal recycling. The PE ratio here is also under ten, while 2010 promises to be a year of accelerating growth.
CHINA NEPSTAR ADS (NPD, current price = $7.31): China Nepstar is the largest drugstore chain in China. The company is expanding rapidly, both via acquisitions and organic growth, and pays a dividend—a sign of its shareholder friendly attitudes.
TIANYIN PHARMACEUTICAL (TPI, current price = $4.81): This is another Chinese microcap that pays a dividend, and generates a 3% yield, in addition to solid prospects for price appreciation. The company received approvals to sell two more drugs from the Chinese government just this week, and looks poised for another record year.http://seekingalpha.com/article/182492-still-bullish-on-chinese-microcap-stocks?source=yahoo
Any guesses on when they will file?
Increased my position 40% on the morning dip.
The perferred method of treatment even up to ten times the price. There was real new news at the forum and it was all good if people would take the time and listen.
Where can i get a transcript of the ANX conf.
TPI a top rated China stock http://www.investors.com/StockResearch/StockCheckup.aspx?Symbol=TPI
XODG added a few more. confused and accumulating.
Yeah, Im just overweighted now with BSPM and had to do something different. Also the dividend is ok too.Looking at ANX to run today too.Dont know what to think of XODG.
TPI Right there with you at 5.30
Wow, Thanks for posting. I will bail today.
Adventrx Pharmaceuticals (ANX) Submits Cancer Drug to NDA Amid Takeover Rumors
By Traci Hogg
ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX) is a biopharmaceutical company founded in 1995 and based in San Diego, California, which focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. The Company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530, a novel emulsion formulation of chemotherapy drug Vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with Cisplatin, as well as to treat advanced or metastatic breast cancer.
If approved, ANX-530 threatens to take market share away from several bigger pharmaceutical companies, including GlaxoSmithKline. This could mean a huge upside to the current share price, especially since the Company has no debt and a low float, as well as millions in cash on hand. Among ADVENTRX's top institutional holders are Carl Icahn's Icahn Capital Management, Renaissance Technologies, UBS AG, the Bank of New York Mellon and Barclay's Global Investors. Beacon Equity Research has the stock listed as "Bullish."
The Company's Principal Executive Officer, Brian M. Culley, will present at the OneMedForum Finance Conference on Wednesday, January 13, 2010. Mr. Culley will discuss ANX-530 as well as another late-stage product candidate, ANX-514 (3 Billion existing market), which is a novel emulsion formulation of the chemotherapy drug Docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.
When interviewed for this article, Principal Executive Officer, Brian Culley was asked about Carl Icahn's interest in the company. Mr. Culley confirmed, "We are well aware that Carl Icahn is a substantial stockholder in ADVENTRX." He went on to add, "In fact, the Icahn affiliates are entitled to have one seat on our board of directors."
Shares of ANX have been volatile amid news of takeover rumors recently reported by Fox Business. When asked about the takeover rumors, Mr. Culley responded, "No comment." This will only serve to fuel the speculation.
Traci Hogg is a small stock trader and business writer, who specializes in investigating successful OTC companies.
Disclosure: Writer is Long ANX, but receives no compensation from the company.
http://newsblaze.com/story/20100110141726trho.nb/topstory.html
6.30 x 6.45 Shortsqueeze coming.
Building up towards the conferance on Wednesday.
A PR about the upcoming uplisting might kick us up to the 8's or higher.
How soon before JBII uplists?
Getting married on Valentines Day.....what a romantic
Whats the deal with the China trip. Is he looking to be able to mass produce the machines before he goes on his promotion spree?
Best post yet. This board needs more like this and a lot less of the Weeeeeeee and Booooom and $300 a share stuff.
So what you are saying is that tomorrow during premarket it will be a buying frenzy.
Ok in for a few cheapies.
Stink bids going off....weeee
Bid price is so low its like throwing your shares in the fire. Good days will come once cell phone warnings become law and are in the news again. I hope everyone hangs onto their shares.
ANX will be a good triple
ADENTRX set to move in on GlaxoSmithKline's lucrative oncology drug
12:41 PM ET, January 4, 2010
Jan 04, 2010 (BAYSTREET NEWSWIRE via COMTEX) -- Like most companies in the sector, ADENTRX (US:ANX) decided to follow the golden rule of biotech finance on Monday: "Raise money when you can."
Despite great news about the filing of their highly anticipated New Drug Application for ANX-530, most investors react to these types of financings in a very bearish fashion (fearing dilution in the worst possible way), I watched shares get beat up pretty badly during the morning part of Monday's session. Still, my former life as an investment advisor taught me that these types of situations often present terrific buying opportunities. I went through the ADVENTRX corporate presentation and wanted to share a few observations with fellow biotech investors. I do apologize ahead of time if I am rehashing prior due diligence, but I want readers to understand that I do have experience following companies who blazed the trail of creating improved equivalent ethical pharmaceutical products. Many of them quickly became multi-billion dollar companies.
There are also many cases were companies have made these kinds of maneuvers with lower profit margin drugs and this path, too, has been very profitable while offering much risk.
The fact that ANX has decided to do this with Oncology products is, in my honest opinion, simply brilliant.
Oncology products offer much higher profit margins and lower managed care hurdles, but ADVENTRX has a proven model to follow and I am happy to elaborate.
First of all, we have to talk about why ADVENTRX can do this.
It's important to understand that the company has developed a unique proprietary emulsion technology to reformulate approved drugs and lower side effects.
In simple terms by improving how a dose is delivered once its in the body you can change the way the body reacts to that drug. A very simple analogy here would be giving someone 3 shots of whisky immediately vs. mixing 3 shots of whisky with a bottle of 7 up and drinking it slowly.
You have changed the way the potent alcohol was delivered to the body (less burning in the mouth etc) but the alcohol still went down the esophagus and into the blood stream. Mission accomplished.
One of the things that makes ADVENTRX such an interesting play, and no doubt one of the reasons why billionaire Carl Icahn and other funds and money managers have purchased so many shares of the company is that even though ANX is an early stage oncology company, it doesn't carry the same risk as other early stage companies. The reason is simple. They have a lower-risk regulatory path.
The type of FDA approval ADVENTRX is seeking is based on a single pharmacokinetic study. The only endpoint is bio-equivalence and that gives the approval process much shorter time lines, lower clinical study costs and lower risk of failure.
Perhaps the one negative with this type of scenario is that the company will not be marketing major new breakthrough like Avastin with no competition, so the stock's upside may be less than if you stumbled across Genetech at this point in their development.
If you're willing to accept that, the upside with ADVENTRX is still tremendous, especially since ANX already has a product on the launching pad: ANX 530 Vinorelbine (Navelbine) Emulsion.
The problem with the current form of GlaxoSmithKline's (US:GSK) Navelbine is that the injection site reaction is 30%.
Understand that Oncology products are notorious for side effects. In most oncology treatment protocols, side effects or toxicity are one of the top reasons patients are not able to complete drug treatment and get the full potential life saving benefit from the treatment.
The company's presentation shows clearly that ANX-530 had considerably less ear vein histopathological toxicity in preclinical trials- an 89 % reduction in injection site reactions. This is highly statistically significant and should bode well with the FDA review committee.
Also in development at ADVENTRX is ANX-514 Docetaxel (Taxotere) emulsion detergent free formulation. Again an easier, softer delivery system designed to reduce hypersensitivity reactions associated with detergents.
The pharmacokinetic study was finished , bio-equivalence not observed. Higher levels during administration were observed but smoothed out during the time curve.
My personal opinion is that if you can deliver more of the drug with less side effects you have potential for better efficacy.
That's always an oncologists first thought: "How far can I push this drug?"
It wasn't a major factor in this bio-equivalent study and no clinical studies will follow to prove this point. If left out here with an approved drug it will be a positive in my opinion. An FDA meeting is planned.
ADVENTRX has already partnered for South Korea and ANX-514 could also have the benefit of reducing the need of high dose steroids in patients. Unfortunately, high dose steroids are a necessary evil in many current oncology treatments and their risk/reward benefits present a delicate balance. Reducing or eliminating them would be a huge advantage for ANX-514.
Another benefit may be less interruption in the treatment therapy schedule. Again, if you can't take the drug your overall survival and relapse free survival rates suffer.
There is also a strong possibility that we may see less nursing time spent managing adverse events with ANX-514. Do you have any idea how much a speciality oncologist nurse gets paid? Do you know how much of their time is spent managing adverse events?
Simple answer to both questions: Too much.
Another advantage should be the use of standard tubing sets. Again, more money, time and headaches saved.
ANX's Docetaxel story gets even better.
The current composition patent expires in 2010 but the last taxotere formulation patent goes until 2013. The molecule is scheduled to becomes free in May 2010, then ADVENTRX gets a brand name product to share for 3 1/2 years.
That's a $3 billion dollar existing market potential.
The company could also potentially get a patent until 2027!
ANX-530 has a $200 million, unpromoted existing market and demand is still growing. ANX-530's patent claim should go until 2025.
Is ADVENTRX going down some dark uncharted alley? Absolutely not.
The path has already been cleared by a couple of current product reformulations.
Abraxane a detergent free formulation , approval based on improvement in response not overall survival studies, reduced hypersensitivity reactions lower rates of neutropenia and faster infusion rates.
Prior to generic entrants in 2001 Taxol sold $1.8 billion dollars, Abraxane sold $335 million dollars in 2008- nearly 40% of the taxane market share in this metastatic breast cancer pie.
Aloxi was the fourth drug in its class for chemotherapy induced nausea and vomiting. Still, Aloxi gained the market share lead in only 2 years.
Finally, most small bio techs are desperate for cash.
In late September, 2009 Adventrx had $3.2 million dollars in cash. By October 2009 Adventrx raised $6 million.
Today, the company announced today that it has signed agreements to purchase shares of its Series E convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ADVENTRX of approximately $19 million dollars.
In a huge tell about how the company is feeling about their chances, ADVENTRX says it plans to use the net proceeds from the offering to fund activities relating to the commercial launch of ANX-530, including acquiring or developing sales, marketing and distribution capabilities and the associated regulatory compliance infrastructure, and to continue the development of ANX-514 in the United States.
Compared to most biotechs with this much upside, ADVENTRX has a relatively low number of outstanding shares and a very small market cap.
They have no debt and at now least 24 months of cash on hand.
Also, ADVENTRX's costs do not include typical high dollar expensive clinical studies. ANX's clinical studies are understandably much, much lower.
In short, ANX is taking high profit drugs, improving delivery and presenting investors with a tremendous buying opportunity.
I believe this is a very solid company with an excellent chance of price share appreciation both in the very short and long term. Mike Burns is a former investment advisor with First Albany and Smith Barney. He now works in the pharmaceutical industry and is a contributor to BioMedReports. Disclosure: Long ANX
Copyright 2010 BAYSTREET NEWSWIRE
http://cxa.marketwatch.com/tsx/en/market/article.aspx?guid=http://system.marketwatch.com/newscloud/docguid/{D96DBEC5-6F21-47A6-9168-FCBDC07993BB}
Best of luck to you. This will be all over the place today.Absolutely , a long term keeper.
The trick is to find the next boomer before it explodes.Im checking the google news and think cell phone EMR is interesting.The Disney deal here is fascinationg and really makes you take a closer look at it. Just that too many traders are in it now.Traders will bail if they even imagine limited upside.
Should start selling off soon. Rebuy for a dime.
This play is just a matter of time. Smart accumulation is now. This will easily surpass the previous 52 week high of .50 The news of the cell phone scare is just getting started.Very few players now. This should pick up with more news.
Cellphone cancer warning: World to follow Maine's lead?
Andrew Thomas | Mon 4th Jan 2010, 05:09 am
Consumer Electronics Features Share this articleThe telecom industry is warning that governments around the world are likely to debate cellphone cancer warnings later this month.
Last week, Maine legislators' announced attempts to force phone makers to affix cigarette-style health warning stickers to their products warning that cellphone use can cause brain cancer, despite a lack of scientific consensus.
State Representative Andrea Boland is pushing for Maine to become the first to require the warnings, saying she 'was convinced from what she had read' that the radiation from cellphones increased the risk of brain cancer when held at the ear, especially in children under 18.
"The main thing is that the warning labels get on there, and when people go to purchase something they have a heads-up that they need to really think about it," said Boland. "This is a big important industry, and it's a small modification to assure people that they should handle them properly."
The Australian telecoms industry expects a worldwide wave of concern when the legislation is debated in the US.
Randal Markey, from the Australian Mobile Telecommunications Association, said it was understandable that people would have concerns about mobile phones because of their experience with health scares such as tobacco and asbestos.
"We do not expect everyone to accept our assurances about mobile phone safety," he said. "Our industry relies on the expert opinion of international health agencies for an overall assessment of health and safety issues. There is no established evidence that radio frequency exposure within internationally accepted safety limits causes adverse health effects."
CLTK Cellphone cancer warning: World to follow Maine's lead?
Andrew Thomas | Mon 4th Jan 2010, 05:09 am
Consumer Electronics Features Share this articleThe telecom industry is warning that governments around the world are likely to debate cellphone cancer warnings later this month.
Last week, Maine legislators' announced attempts to force phone makers to affix cigarette-style health warning stickers to their products warning that cellphone use can cause brain cancer, despite a lack of scientific consensus.
State Representative Andrea Boland is pushing for Maine to become the first to require the warnings, saying she 'was convinced from what she had read' that the radiation from cellphones increased the risk of brain cancer when held at the ear, especially in children under 18.
"The main thing is that the warning labels get on there, and when people go to purchase something they have a heads-up that they need to really think about it," said Boland. "This is a big important industry, and it's a small modification to assure people that they should handle them properly."
The Australian telecoms industry expects a worldwide wave of concern when the legislation is debated in the US.
Randal Markey, from the Australian Mobile Telecommunications Association, said it was understandable that people would have concerns about mobile phones because of their experience with health scares such as tobacco and asbestos.
"We do not expect everyone to accept our assurances about mobile phone safety," he said. "Our industry relies on the expert opinion of international health agencies for an overall assessment of health and safety issues. There is no established evidence that radio frequency exposure within internationally accepted safety limits causes adverse health effects."
Thats nothing compared to placing the EMR recievers next to your brain......everytime you use a cellphone.CLTK
Looks like the Maine legislation will pass. Then more states/areas are likely to follow with similiar cell phine warnings.As awareness grows CLTK will go from an almost profitable entity to a booming business. Five cents wont be seen again.Light the fires and kick the tires. This will be a multibagger.
CLTK US mobile phones to get health warnings?
Maine and San Fran lawmakers mull brain cancer cautions
By Mark Harris in Seattle
18 hours ago | Tell us what you think [ 1 comments ]
Could the US get cigarette-style health warnings for mobiles?
If legislators in Maine and San Francisco have their way, American mobile phones will soon carry warnings about radiation and even brain cancer.
The New York Times is reporting that a Democrat representative in Maine is proposing that a state law requiring cellphone makers to put warnings on packaging.
Andrea Boland is said to be 'convinced' that radiation from cellphones increases the chance of brain cancer, particularly in children.
'Emergency' warnings needed?
A spokesperson for Maine's State Senate president said that the last-minute legislation was accepted as an emergency because there are nearly one million mobile phones in the state, "and if there's a need to put these warning labels on them, doing it sooner rather than later is probably better."
San Francisco is considering its own warning plans this year, with a local law that would compel phone makers to display the amount of radiation a handset emits.
In the UK, the Mobile Telecommunications and Health Research Programme (MTHR) found no evidence to link short-term (less than 10 years') mobile phone use with cancers of the brain and nervous system. However, it noted that cancers are rarely detectable until 10 to 15 years after the cancer-producing event, and few people have used mobile phones for that long.
If in doubt, zap a rat
Researchers at North Carolina's Research Triangle Park are currently conducting a five-year, $25 million (£15m) study that involves exposing nearly 1,000 rats to electromagnetic radiation at a similar intensity to that given off by mobile phones.
"I anticipate either no correlation or, if anything is seen at all, it won't be a strong signal," said the study's director. "There's no biological basis explaining why someone would expect to see adverse effects from cellphone radiation."
http://www.techradar.com/news/world-of-tech/us-mobile-phones-to-get-health-warnings--660953
CLTK....... N.Y. Times article January 1,2010............."In Maine, Democrats have a large majority in the House, and Ms. Boland said she was receiving support from fellow Democratic legislators for her measure. She said she used her cellphone “a lot less” than she used to, and now only on speakerphone or with an earpiece.
“The main thing is that the warning labels get on there, and when people go to purchase something, they have a heads-up that they need to really think about it,” Ms. Boland said. “This is a big important industry, and it’s a small modification to assure people that they should handle them properly.”....Maine...San Francisco...France...India...Once this passes the Maine house it will likely start passing in others areas. Ground floor opportunity now with CLTK http://www.nytimes.com/2010/01/02/us/02cell.html
N.Y. Times article January 1,2010............."In Maine, Democrats have a large majority in the House, and Ms. Boland said she was receiving support from fellow Democratic legislators for her measure. She said she used her cellphone “a lot less” than she used to, and now only on speakerphone or with an earpiece.
“The main thing is that the warning labels get on there, and when people go to purchase something, they have a heads-up that they need to really think about it,” Ms. Boland said. “This is a big important industry, and it’s a small modification to assure people that they should handle them properly.”....Maine...San Francisco...France...India...Once this passes the Maine house it will likely start passing in others areas. Ground floor opportunity now with CLTK http://www.nytimes.com/2010/01/02/us/02cell.html
EOD seller wanted out. Dropped the price down. No matter what price you got in for .01-.10 it doesnt change the fact that this is one you just have to hold onto. It represents a ticking time bomb. Just one good size contract announcement after the EMR bills pass and this turns into a big gainer. Until then you have to sit on your hands here and just wait out events.This proves difficult for some.Most will take a few hundered bucks on some penny moves but if you want to make the big bucks you will have to wait things out.